107 related articles for article (PubMed ID: 8605163)
21. Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein.
Rios-Steiner JL; Schenone M; Mochalkin I; Tulinsky A; Castellino FJ
J Mol Biol; 2001 May; 308(4):705-19. PubMed ID: 11350170
[TBL] [Abstract][Full Text] [Related]
22. Relationships between structure and function of tissue-type plasminogen activator.
Rijken DC
Klin Wochenschr; 1988; 66 Suppl 12():33-9. PubMed ID: 3126346
[TBL] [Abstract][Full Text] [Related]
23. Ligand binding to the tissue-type plasminogen activator kringle 2 domain: structural characterization by 1H-NMR.
Byeon IJ; Kelley RF; Mulkerrin MG; An SS; Llinás M
Biochemistry; 1995 Mar; 34(9):2739-50. PubMed ID: 7893685
[TBL] [Abstract][Full Text] [Related]
24. Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli.
Manosroi J; Tayapiwatana C; Götz F; Werner RG; Manosroi A
Appl Environ Microbiol; 2001 Jun; 67(6):2657-64. PubMed ID: 11375177
[TBL] [Abstract][Full Text] [Related]
25. Isolation, purification and 1H-NMR characterization of a kringle 5 domain fragment from human plasminogen.
Thewes T; Ramesh V; Simplaceanu EL; Llinás M
Biochim Biophys Acta; 1987 Apr; 912(2):254-69. PubMed ID: 3030435
[TBL] [Abstract][Full Text] [Related]
26. Role of tryptophan-74 of the recombinant kringle 2 domain of tissue-type plasminogen activator in its omega-amino acid binding properties.
De Serrano VS; Castellino FJ
Biochemistry; 1992 Apr; 31(13):3326-35. PubMed ID: 1554717
[TBL] [Abstract][Full Text] [Related]
27. Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
Lee SB; Oh HK; Kim HK; Joe YA
Protein Expr Purif; 2006 Nov; 50(1):1-8. PubMed ID: 16854593
[TBL] [Abstract][Full Text] [Related]
28. Domain structure and interactions of recombinant urokinase-type plasminogen activator.
Novokhatny V; Medved L; Mazar A; Marcotte P; Henkin J; Ingham K
J Biol Chem; 1992 Feb; 267(6):3878-85. PubMed ID: 1310986
[TBL] [Abstract][Full Text] [Related]
29. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
[TBL] [Abstract][Full Text] [Related]
30. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
31. Structure of the plasminogen kringle 4 binding calcium-free form of the C-type lectin-like domain of tetranectin.
Nielbo S; Thomsen JK; Graversen JH; Jensen PH; Etzerodt M; Poulsen FM; Thøgersen HC
Biochemistry; 2004 Jul; 43(27):8636-43. PubMed ID: 15236571
[TBL] [Abstract][Full Text] [Related]
32. Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla).
Kemball-Cook G; Johnson DJ; Tuddenham EG; Harlos K
J Struct Biol; 1999 Oct; 127(3):213-23. PubMed ID: 10544046
[TBL] [Abstract][Full Text] [Related]
33. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage.
Renatus M; Stubbs MT; Huber R; Bringmann P; Donner P; Schleuning WD; Bode W
Biochemistry; 1997 Nov; 36(44):13483-93. PubMed ID: 9354616
[TBL] [Abstract][Full Text] [Related]
34. Metal-dependent conformational changes in a recombinant vWF-A domain from human factor B: a solution study by circular dichroism, fourier transform infrared and (1)H NMR spectroscopy.
Hinshelwood J; Perkins SJ
J Mol Biol; 2000 Apr; 298(1):135-47. PubMed ID: 10756110
[TBL] [Abstract][Full Text] [Related]
35. The effects of ligand binding on the backbone dynamics of the kringle 1 domain of human plasminogen.
Zajicek J; Chang Y; Castellino FJ
J Mol Biol; 2000 Aug; 301(2):333-47. PubMed ID: 10926513
[TBL] [Abstract][Full Text] [Related]
36. A refined kinetic analysis of plasminogen activation by recombinant bovine tissue-type plasminogen activator indicates two interconvertible activator forms.
Johnsen LB; Ravn P; Berglund L; Petersen TE; Rasmussen LK; Heegaard CW; Rasmussen JT; Benfeldt C; Fedosov SN
Biochemistry; 1998 Sep; 37(36):12631-9. PubMed ID: 9730836
[TBL] [Abstract][Full Text] [Related]
37. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
Rezaie AR
Biochemistry; 1998 Sep; 37(38):13138-42. PubMed ID: 9748320
[TBL] [Abstract][Full Text] [Related]
38. Structural/functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide.
Frank PS; Douglas JT; Locher M; Llinás M; Schaller J
Biochemistry; 2003 Feb; 42(4):1078-85. PubMed ID: 12549929
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
40. Cloning and expression of truncated form of tissue plasminogen activator in Leishmania tarentolae.
Nazari R; Davoudi N
Biotechnol Lett; 2011 Mar; 33(3):503-8. PubMed ID: 21120587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
